A Shifting Paradigm: Translating Research into Treatment Approaches for ALS
Many providers lack knowledge regarding amyotrophic lateral sclerosis (ALS) and may be unaware of available information. Arming providers with an expansive understanding is extremely important. This activity highlights the need for education efforts to provide healthcare providers with clinical updates and tools to ensure that their patients receive the best possible care. This multimodal educational program from BRAINWeek will have a positive impact on patient outcomes and aims to provide neurologists, primary care physicians, physical therapists, clinical pharmacists, physicians assistants, nurse practitioners, and other HCPs with an experience that fills the knowledge gaps surrounding ALS.
This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America, Inc.
This activity is provided by Global Education Group
The educational design of this activity addresses the needs of neurologists, gastroenterologists, occupational therapists, nutritionists, physiotherapists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and other HCPs involved in the treatment of patients with ALS.
After completing this activity, the participant should be better able to:
- Outline the clinical relevance of genetic mutations in the etiology of ALS
- Outline the disease progression and impact that ALS has on patient lives
- Describe the challenges pertaining to and the need for timely and accurate diagnosis of ALS
- Review the current treatment landscape for ALS, including safety and efficacy
- Summarize the pipeline drugs and emerging treatment options for ALS
- Identify the importance of utilizing the collaborative care model to optimize patient outcomes for those struggling with ALS
Richard Bedlack, Jr., MD, PhD, MS
Professor of Neurology
Xiaoyan Li, MD, PhD
Assistant Professor of Neurology
Duke University School of Medicine
Physician Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-0000-22-346-H01-P)
This is a knowledge-based activity.
This activity was released on 12/5/2022 and is valid for one year. Requests for credit must be made no later than 12/5/2023.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must the participant must complete and pass the posttest with a score of at least 70% and complete the evaluation/application for credit. Certificates will then be available for download. Pharmacists: Credit will be awarded via CPE Monitor 60 days post the enduring activity.
Fee & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
All relevant financial relationships have been mitigated.
Name of Faculty or Presenter
Reported Financial Relationship
|Richard Bedlack, Jr., MD, PhD, MS|
Consulting Fee (e.g., Advisory Board): AB Science, Alexion, ALSA, Amylyx, Apellis, Biogen, Black Swan, Brainstorm Cell, Corcept, Cytokinetics, GenieUs, ITF Pharma,Mallinkrodt, New Biotic, Orphazyme, Shinkei, Woolsey Pharma Contracted Research (Principal Investigators must provide information, even if received by the institution): Orion, MediciNova Speakers' Bureau: Amylyx
|Xiaoyan Li, MD, PhD||Nothing to disclose|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 ACCME (All Other)
- 1.00 ACCME (MD/DO Only)
- 1.00 ACPE Pharmacy
- 1.00 ANCC
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)